Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$60.71

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $60.71 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $24.01 1
GENZYME CORPORATION $19.62 1
Lilly USA, LLC $17.08 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $60.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.0107/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201991368 CMS
GENZYME CORPORATION $19.6204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233695767 CMS
Lilly USA, LLC $17.0804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186600368 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

99 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,154.68 12/31/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749962
Principal investigator 1 PFIZER INC. $5,544.84 12/03/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228743710
Principal investigator 1 PFIZER INC. $4,381.50 11/26/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228728565
Principal investigator 1 PFIZER INC. $1,600.80 11/25/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228738041
Principal investigator 1 PFIZER INC. $6,237.60 09/19/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228749889
Principal investigator 1 PFIZER INC. $2,277.00 09/12/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228750761
Principal investigator 1 PFIZER INC. $19,064.08 08/23/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228766135
Principal investigator 1 PFIZER INC. $6,575.70 07/29/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228774001
Principal investigator 1 Incyte Corporation $2,521.80 07/23/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603053
Principal investigator 1 Incyte Corporation $2,289.00 07/23/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603056
Principal investigator 1 PFIZER INC. $7,562.40 07/17/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773325
Principal investigator 1 PFIZER INC. $12,254.88 07/02/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228771758
Principal investigator 1 Incyte Corporation $90.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602920
Principal investigator 1 Incyte Corporation $552.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602951
Principal investigator 1 Incyte Corporation $50.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602983
Principal investigator 1 Incyte Corporation $50.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602987
Principal investigator 1 Incyte Corporation $1,500.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602997
Principal investigator 1 Incyte Corporation $150.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603000
Principal investigator 1 Incyte Corporation $35.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603004
Principal investigator 1 Incyte Corporation $1,750.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603011
Principal investigator 1 Incyte Corporation $8,000.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603015
Principal investigator 1 Incyte Corporation $119.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603031
Principal investigator 1 Incyte Corporation $119.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603036
Principal investigator 1 Incyte Corporation $35.00 06/20/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603047
Principal investigator 1 Incyte Corporation $125.00 06/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602990
Principal investigator 1 Incyte Corporation $50.00 06/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602994
Principal investigator 1 Eli Lilly and Company $2,475.00 06/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187888212
Principal investigator 1 PFIZER INC. $10,358.28 05/30/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228772104
Principal investigator 1 Incyte Corporation $1,973.15 05/21/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602943
Principal investigator 1 Incyte Corporation $80.00 05/19/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602924
Principal investigator 1 PFIZER INC. $8,137.10 05/16/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228773649
Principal investigator 1 Incyte Corporation $90.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602928
Principal investigator 1 Incyte Corporation $150.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602932
Principal investigator 1 Incyte Corporation $125.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602936
Principal investigator 1 Incyte Corporation $119.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602947
Principal investigator 1 Incyte Corporation $70.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602958
Principal investigator 1 Incyte Corporation $90.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602961
Principal investigator 1 Incyte Corporation $119.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602970
Principal investigator 1 Incyte Corporation $276.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603028
Principal investigator 1 Incyte Corporation $828.00 05/09/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603042
Principal investigator 1 PFIZER INC. $7,457.52 05/03/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228723604
Principal investigator 1 Incyte Corporation $180.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602940
Principal investigator 1 Incyte Corporation $476.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602954
Principal investigator 1 Incyte Corporation $140.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602966
Principal investigator 1 Incyte Corporation $290.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602973
Principal investigator 1 Incyte Corporation $276.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602978
Principal investigator 1 Incyte Corporation $1,750.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603007
Principal investigator 1 Incyte Corporation $108.00 05/02/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603019
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,113.10 04/28/2025 Non-covered Recipient Entity
Qcare Site Services Inc
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235994405
Principal investigator 1 Incyte Corporation $2,775.00 04/23/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602879
Principal investigator 1 Incyte Corporation $1,834.40 04/23/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603038
Principal investigator 1 Incyte Corporation $776.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602885
Principal investigator 1 Incyte Corporation $70.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602889
Principal investigator 1 Incyte Corporation $119.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602893
Principal investigator 1 Incyte Corporation $828.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602897
Principal investigator 1 Incyte Corporation $100.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602900
Principal investigator 1 Incyte Corporation $150.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602903
Principal investigator 1 Incyte Corporation $552.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602908
Principal investigator 1 Incyte Corporation $120.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602912
Principal investigator 1 Incyte Corporation $238.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602916
Principal investigator 1 Incyte Corporation $70.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603023
Principal investigator 1 Incyte Corporation $238.00 04/16/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240603050
Principal investigator 1 PFIZER INC. $6,031.98 04/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228779753
Principal investigator 1 Incyte Corporation $2,077.00 03/24/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602795
Principal investigator 1 Incyte Corporation $1,966.85 03/24/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602858
Principal investigator 1 Incyte Corporation $2,077.00 03/24/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602862
Principal investigator 1 PFIZER INC. $6,624.14 03/06/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228796109
Principal investigator 1 PFIZER INC. $3,692.16 03/04/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228795380
Principal investigator 1 Incyte Corporation $104.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602797
Principal investigator 1 Incyte Corporation $1,380.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602826
Principal investigator 1 Incyte Corporation $140.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602829
Principal investigator 1 Incyte Corporation $320.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602832
Principal investigator 1 Incyte Corporation $1,978.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602840
Principal investigator 1 Incyte Corporation $476.00 03/03/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602843
Principal investigator 1 Incyte Corporation $1,973.15 02/21/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602805
Principal investigator 1 PFIZER INC. $52.44 02/11/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1228760708
Principal investigator 1 Incyte Corporation $54.00 02/07/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602800
Principal investigator 1 Incyte Corporation $310.00 02/07/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602811
Principal investigator 1 Incyte Corporation $595.00 02/07/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602822
Principal investigator 1 Incyte Corporation $175.00 02/07/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602854
Principal investigator 1 Incyte Corporation $16.77 02/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602836
Principal investigator 1 Incyte Corporation $3.96 02/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602846
Principal investigator 1 Incyte Corporation $63.96 02/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602848
Principal investigator 1 Incyte Corporation $23.74 02/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602850
Principal investigator 1 Incyte Corporation $2,077.00 01/27/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602814
Principal investigator 1 Incyte Corporation $2,077.00 01/27/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602817
Principal investigator 1 Incyte Corporation $1,438.45 01/27/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602871
Principal investigator 1 Incyte Corporation $2,077.00 01/27/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602875
Recipient E.R. Squibb & Sons, L.L.C. $2,042.82 01/17/2025 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1236002245
Principal investigator 1 Eli Lilly and Company $31,600.92 01/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1187889072
Principal investigator 1 Incyte Corporation $90.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602768
Principal investigator 1 Incyte Corporation $276.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602773
Principal investigator 1 Incyte Corporation $2,314.10 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602777
Principal investigator 1 Incyte Corporation $2,077.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602780
Principal investigator 1 Incyte Corporation $119.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602783
Principal investigator 1 Incyte Corporation $35.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602787
Principal investigator 1 Incyte Corporation $2,289.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602791
Principal investigator 1 Incyte Corporation $2,077.00 01/06/2025 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240602868
Principal investigator 1 ABBVIE INC. $2,066.30 01/02/2025 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
M16-045 - Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1202436330

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935